title: NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
abstract: Oral levodopa is the current baseline therapy in the management of Parkinson's disease, but nonmotor complications and therapy-related dyskinesias pose an important challenge for clinicians. Glutamate receptors have been implicated in the neurodegenerative process of Parkinson's disease and also in the development of levodopa-induced dyskinesias. This article discusses the role of NMDA receptors in Parkinson's disease and their modulation as a possible therapeutic approach.
authors.affiliation: Department of Neurology, University of Szeged, Semmelweis utca 6, H-6725 Szeged, Hungary.
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Majláth
authors.forename: László
authors.initials: L
authors.lastname: Vécsei
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018691:Excitatory Amino Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D014364:Tryptophan / Q000378:metabolism
chemical_list: D000978:Antiparkinson Agents; D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; D014364:Tryptophan